Article
Oncology
Diya M. Sabu, Jeska Kroes, Charles Gilham, Ann Fleming, Fergal C. Kelleher
Summary: Basal cell carcinomas are common in Caucasian populations, with the Hedgehog pathway playing a significant role in their development. This case highlights the dramatic response of an elderly patient with untreated sporadic Basal cell carcinoma to the Hedgehog pathway inhibitor Vismodegib, enabling definitive treatment to be pursued.
CURRENT PROBLEMS IN CANCER
(2021)
Article
Dermatology
Tanja Mesti, Masa Sever, Janja Ocvirk
Summary: Vismodegib has demonstrated significant efficacy in the treatment of laBCC, multiple BCC, and G-G Syn patients in Slovenia, achieving disease control rates of 95% to 100%.
Article
Medicine, General & Internal
Nicolas Bertrand, Pierre Guerreschi, Nicole Basset-Seguin, Philippe Saiag, Alain Dupuy, Sophie Dalac-Rat, Veronique Dziwniel, Cesar Depoortere, Alain Duhamel, Laurent Mortier
Summary: Neoadjuvant vismodegib treatment reduces the risk of surgery for patients with locally advanced basal cell carcinoma, minimizing the functional and aesthetic consequences of surgery.
Article
Dermatology
Mustafa Gurbuz, Izzet Dogan, Erman Akkus, Hande Ermis, Gungor Utkan, Sezai Vatansever, Faruk Tas
Summary: The study evaluated the efficacy of vismodegib treatment in locally advanced and metastatic basal cell carcinoma, showing it was well tolerated and effective in real-world settings. Treatment responses were most commonly seen within 2 months of initiation, with chemotherapy post-vismodegib showing significant improvement in overall survival compared to no treatment or surgery. The most common adverse events included fatigue, muscle spasms, alopecia, and weight loss.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Helene Marescassier, Lea Dousset, Marie Beylot-Barry, Philippe Celerier, Loic Vaillant, Christophe Bedane, Franck Leclere, Ewa Wierzbicka-Hainaut, Marie Masson Regnault
Summary: In a retrospective multicenter study, factors associated with non-response to vismodegib in patients with locally advanced basal cell carcinomas (laBCC) were identified. Muscle involvement, history of radiotherapy, and intermittent use of vismodegib were significantly associated with non-response. Further studies are needed to confirm these findings due to the limited sample size.
Review
Oncology
Gianluca Nazzaro, Valentina Benzecry, Maria A. Mattioli, Nerina Denaro, Giada A. Beltramini, Angelo V. Marzano, Emanuela Passoni
Summary: Basal cell carcinoma (BCC) is a common type of malignancy. Locally advanced BCC (laBCC) is an aggressive form of BCC that cannot be treated with surgery or radiotherapy. Sonidegib, a Hedgehog inhibitor, has shown efficacy in treating laBCCs. This study reports the experience with Sonidegib treatment in laBCC patients using retrospectively collected data.
Article
Ophthalmology
Assaf Gershoni, Alon Tiosano, Meydan Ben Ishai, Edward Barayev, Guy J. Ben Simon, Iftach Yassur
Summary: The study evaluated the impact of locally advanced periocular basal cell carcinoma (POLA-BCC) on health-related quality of life (HRQoL) and the efficacy of vismodegib treatment. Results showed that patients with POLA-BCC had significantly impaired overall functioning at baseline, but demonstrated significant improvement at the last follow-up.
Article
Medicine, General & Internal
Austin R. Swisher, Mark J. Landau, Allison B. Davila, Armando A. Davila, Caryn Zagaynov, Christopher A. Bobbitt, Darren S. Leong, Alexander Y. Chang, Walter T. Chang
Summary: This article describes three cases of locally advanced basal cell carcinoma (BCC) of the extremities treated with vismodegib, resulting in significant clinical responses and tumor size reduction, eliminating the need for complex reconstructive surgery or amputation.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Dermatology
Cecile Juzot, Anne Isvy-Joubert, Amir Khammari, Anne-Chantal Knol, Jean-Michel Nguyen, Brigitte Dreno
Summary: This study analyzed 61 patients treated with vismodegib for locally advanced or multiple BCC, and demonstrated for the first time that increased treatment duration is correlated with a decreased risk of relapse. However, no predictive factors for response to vismodegib were identified.
EUROPEAN JOURNAL OF DERMATOLOGY
(2022)
Article
Oncology
Laura Eibenschutz, Silvia Caputo, Emanuela Camera, Anna Carbone, Vitaliano Silipo, Emilia Migliano, Caterina Aurizi, Carlo Cota, Pasquale Frascione, Barbara Bellei
Summary: Nevoid basal cell carcinoma syndrome (NBCCS) is a genetic disorder that predisposes individuals to basal cell carcinoma (BCC) due to mutations in genes related to the Hedgehog (Hh) pathway. Somatic mutations in this pathway are associated with sporadic BCC, and targeting this pathway with drugs like vismodegib and sonidegib could potentially be a therapeutic option. These drugs impact fibroblast functions supporting tumor growth and could be considered for BCC therapy regardless of the mutation status of Hh components in neoplastic cells.
Review
Chemistry, Medicinal
Neha Gupta, Emily S. Ruiz
Summary: Basal cell carcinoma is the most common cancer in Caucasians and requires a multi-modal approach for treatment.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Review
Oncology
Paolo Bossi, Paolo A. Ascierto, Nicole Basset -Seguin, Brigitte Dreno, Reinhard Dummer, Axel Hauschild, Peter Mohr, Roland Kaufmann, Giovanni Pellacani, Susana Puig, David Moreno-Ramirez, Caroline Robert, Alex Stratigos, Ralf Gutzmer, Paola Queirolo, Pietro Quaglino, Ketty Peris
Summary: This article presents the long-term management strategy for advanced BCC patients treated with systemic therapy. Hedgehog inhibitors Sonidegib and Vismodegib are first-line treatments for advanced BCC, but long-term use of hedgehog inhibitors is often challenging due to tolerability issues. However, various strategies for adverse effect management, such as dose interruptions, on-label alternate-day dosing, and supportive medications, are available.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Dermatology
Arsh Patel, Jane S. Kim, Jason Liss, Lauren Howard, Sin-Ho Jung, Meenal Kheterpal
Summary: Management of patients with locally advanced basal cell carcinoma using traditional strategies has shown suboptimal outcomes. Targeted treatments, including hedgehog inhibitor therapy, have limitations as monotherapy. Evidence-based outcomes from literature support the use of adjunctive therapies post-HHIT to improve treatment response in laBCC patients.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Ralf Gutzmer, Carmen Loquai, Caroline Robert, Brigitte Dreno, Alexander Guminski, Karl Lewis, Ramon Arntz, Serena Martelli, Nicholas Squittieri, Meenal Kheterpal
Summary: This analysis compared the incidence and onset of adverse events in patients treated with sonidegib and vismodegib for basal cell carcinoma. Sonidegib-treated patients experienced lower incidence and delayed onset of adverse events compared to those treated with vismodegib.
DERMATOLOGY AND THERAPY
(2021)
Review
Cell Biology
Giulia Vallini, Laura Calabrese, Costanza Canino, Emanuele Trovato, Stefano Gentileschi, Pietro Rubegni, Linda Tognetti
Summary: Non-melanoma skin cancers, particularly basal cell carcinoma (BCC), are common neoplasms worldwide. The majority of sporadic BCC cases have mutations in Hedgehog pathway genes, leading to abnormal activation of GLI transcription factors. The management of advanced BCCs, including metastatic and locally advanced cases, that are not eligible for surgery or radiotherapy is challenging. The discovery of mutations in the Hh signaling pathway has led to the development of Hh pathway inhibiting agents, but their use is limited due to adverse events and drug resistance.
